Boc-N(Me)Leu-Tyr(Bn)-NHtBu | 217172-32-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-N(Me)Leu-Tyr(Bn)-NHtBu
• 英文别名: tert-butyl N-[(2S)-1-[[(2S)-1-(tert-butylamino)-1-oxo-3-(4-phenylmethoxyphenyl)propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methylcarbamate
• CAS: 217172-32-2
• 化学式: C₃₂H₄₇N₃O₅
• 分子量: 553.742
• InChiKey: HHEVSHWSCMYHMH-SVBPBHIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  40
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  97
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Boc-N(Me)Leu-Tyr(Bn)-NHtBu 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-4-Methyl-2-methylamino-pentanoic acid [(S)-2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethyl]-amide
  参考文献：
  名称：

  Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers

  摘要：

  Selective N-type voltage sensitive calcium channel (VSCC) blockers have shown efficacy in several animal models of stroke and pain. In the process of searching for small molecule N-type calcium channel blockers, we have identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR-32 assays). SAR and pharmacological evaluation of this series are described, (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00359-5
• 作为产物：
  描述：

  (S)-[2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethyl]-carbamic acid tert-butyl ester 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 Boc-N(Me)Leu-Tyr(Bn)-NHtBu
  参考文献：
  名称：

  Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers

  摘要：

  Selective N-type voltage sensitive calcium channel (VSCC) blockers have shown efficacy in several animal models of stroke and pain. In the process of searching for small molecule N-type calcium channel blockers, we have identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR-32 assays). SAR and pharmacological evaluation of this series are described, (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00359-5

文献信息

• N,N-Dialkyl-dipeptidylamines as novel N-type calcium channel blockers
  作者：Lain-Yen Hu、Todd R Ryder、Michael F Rafferty、Wayne L Cody、Susan M Lotarski、George P Miljanich、Elizabeth Millerman、David M Rock、Yuntao Song、Sally J Stoehr、Charles P Taylor、Mark L Weber、Balazs G Szoke、Mark G Vartanian

  DOI：10.1016/s0960-894x(99)00100-6

  日期：1999.3

  Selective N-type voltage sensitive calcium channel (VSCC) blockers have shown utility in several models of stroke amid pain. We are especially interested in small molecule N-type calcium channel blockers for therapeutic use. Herein, we report a series of N,N-dialkyl-dipeptidylamines with potent functional activity at N-type VSCCs and in vivo efficacy. The synthesis, SAR, and pharmacological evaluation of this series are discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.
• US6117841A
  申请人：——

  公开号：US6117841A

  公开（公告）日：2000-09-12
• Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers
  作者：Lain-Yen Hu、R. Todd Ryder、Michael F. Rafferty、David J. Dooley、Joann J. Geer、Susan M. Lotarski、George P. Miljanich、Elizabeth Millerman、David M. Rock、Sally J. Stoehr、Balazs G. Szoke、Charles P. Taylor、Mark G. Vartanian

  DOI：10.1016/s0960-894x(99)00359-5

  日期：1999.8

  Selective N-type voltage sensitive calcium channel (VSCC) blockers have shown efficacy in several animal models of stroke and pain. In the process of searching for small molecule N-type calcium channel blockers, we have identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR-32 assays). SAR and pharmacological evaluation of this series are described, (C) 1999 Elsevier Science Ltd. All rights reserved.